Marathon Asset Management closed a senior-secured credit facility to finance H.I.G. Capital’s acquisition of SkinCure Oncology Intermediate LLC. SkinCure Oncology’s executive team, led by CEO Kerwin Brandt, will continue to lead the company and remain significant shareholders.

SkinCure Oncology is a leading provider of image-guided superficial radiation therapy (IG-SRT), a non-invasive treatment primarily for nonmelanoma skin cancer (NMSC). Unlike conventional surgical approaches, IG-SRT requires no incisions or reconstructive surgery, allowing patients to carry on with normal activities, while also offering cosmetic benefits for patients worried about scarring. SkinCure Oncology’s GentleCure™ Experience, IG-SRT is accessible through more than 500 physicians nationwide, with over 100,000 patients treated using this technology.

“SkinCure Oncology has a tremendous track record for delivering outcomes for both its physician partners and patients,” said Curtis Lueker, Marathon’s Head of Direct Lending. “The company is an established leader in the industry, and we are excited to partner with H.I.G. and their strong management team to execute on their strategic vision and expansion to provide increased options and access to care for patients with NMSC.”

“The power of Marathon's integrated investment platform, utilizing the expertise and combined capabilities of our dedicated Healthcare Finance and Direct Lending teams, enabled us to provide a reliable, thoughtful, and efficient financing solution for a best-in-class sponsor in H.I.G.,” said Bruce Richards, Marathon’s Chairman and CEO. “Marathon’s Private Credit platform is designed as a one-stop shop, offering corporate, asset-based, and capital solutions, including senior and junior financings ranging from $50 million to $250 million.”